Great Basin Scientific (NASDAQ: GBSN) and Ocular Therapeutix (NASDAQ:OCUL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares Great Basin Scientific and Ocular Therapeutix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Great Basin Scientific 2,588.36% N/A 168.06%
Ocular Therapeutix -3,005.52% -101.03% -69.76%

Insider and Institutional Ownership

53.4% of Ocular Therapeutix shares are held by institutional investors. 26.1% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Great Basin Scientific and Ocular Therapeutix’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Great Basin Scientific $3.15 million 0.04 -$30.80 million N/A N/A
Ocular Therapeutix $1.90 million 96.50 -$54.64 million ($2.13) -2.96

Great Basin Scientific has higher revenue and earnings than Ocular Therapeutix.

Risk & Volatility

Great Basin Scientific has a beta of 5.09, meaning that its share price is 409% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Great Basin Scientific and Ocular Therapeutix, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Great Basin Scientific 0 0 0 0 N/A
Ocular Therapeutix 0 2 4 0 2.67

Ocular Therapeutix has a consensus price target of $24.00, suggesting a potential upside of 280.35%. Given Ocular Therapeutix’s higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Great Basin Scientific.

Summary

Great Basin Scientific beats Ocular Therapeutix on 6 of the 11 factors compared between the two stocks.

Great Basin Scientific Company Profile

Great Basin Scientific, Inc. is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious diseases, especially hospital-acquired infections. Its commercially available tests are clostridium difficile (C. diff) and Group B Strep. Its system includes an analyzer and a diagnostic cartridge. Each analyzer contains a module into, which individual test cartridges are placed. Its other diagnostic assays in the late stages of product development include a pre-surgical nasal screen for Staphylococcus aureus (SA), food borne pathogen panel, panel for candida blood infections, test for pertussis and a test for Chlamydia tracomatis (CT)/Neisseria gonorrhea (NG). The Company also has a pipeline of assays in an early stage of development, including respiratory testing and sepsis (blood infection) panels. It markets a platform of molecular testing in small to medium sized hospitals.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. It also has an intravitreal hydrogel depot, which is in preclinical development for the treatment of diseases and conditions of the back of the eye, including wet age-related macular degeneration (wet AMD).

Receive News & Ratings for Great Basin Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Great Basin Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.